Strumento inattivo

Altre lingue Coeptis Therapeutics, Inc. OTC Markets

Azioni

COEP

US19207C1045

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Coeptis Therapeutics : CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK OF COEPTIS THERAPEUTICS HOLDINGS, INC Form 8 K	20/06
Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering	20/06
Coeptis Therapeutics Holdings, Inc. announced that it has received $4.3 million in funding	14/06
Coeptis Therapeutics Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting	31/05
Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting	30/05
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024	08/05
Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene and Cell Therapy 27th Annual Meeting	03/05
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on receiving the 2024 Chancellor s Distinguished Research Award	03/04
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award	02/04
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK	27/02
Coeptis Therapeutics Holdings, Inc. Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK	26/02
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections	07/02
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-In-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections	07/02
Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024	04/01
Coeptis Therapeutics to Present at the Emerging Growth Conference	04/12
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Coeptis Therapeutics Holdings, Inc. announced that it has received $2 million in funding	03/11
Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023	31/10/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Coeptis Therapeutics, Inc. OTC Markets

Azioni

COEP

US19207C1045

Altre lingue

Filtri